Jersey City, New Jersey—July 3, 2006—Quantum Genomics Corp (QGC), a global biotechnology company seeking to transform the discoveries and developments of academic research into breakthrough treatments for human disease, announces today that it has chosen to set up its European headquarters in Massy, close to Paris. Lionel Ségard, recently appointed CEO of the parent company, will be President of the new European subsidiary.

The choice of Massy, an area just south of Paris that has a high concentration of technology activities, will facilitate the identification and development of innovative projects in the field of human health. The offices are already operational and are the base from which the company will recruit key members of staff, network with European scientists, and generally develop the business.

“The opening of QGC’s European offices is the first major step in developing our activities,” said Ségard. “It is important to have a base in Europe from which to build and maintain close contact with European scientists to bring to maturity healthcare projects.”

“This move sends QGC on its way to becoming a significant international player,” said Jonathan McCann, board member of QGC. “Our European presence will be a bridge between the two regions in the world which have the most dynamic health research activities, and will increase the chances of bringing this research to a successful conclusion.”

The European office contact details are:

Quantum Genomics Corp SAS
L’Odyssée
2-12, chemin des Femmes
91300 Massy
France
Tel: 01 60 13 76 80
Fax: 01 60 12 59 10